Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：560頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Obstructive Pulmonary Disease (COPD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Obstructive Pulmonary Disease (COPD) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Obstructive Pulmonary Disease (COPD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Obstructive Pulmonary Disease (COPD) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Chronic Obstructive Pulmonary Disease (COPD) Overview 8
Therapeutics Development 9
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies 11
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes 21
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance 23
Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies 27
Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes 40
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 41
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 152
Drug Profiles 175
Chronic Obstructive Pulmonary Disease (COPD) - Recent Pipeline Updates 456
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 525
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 529
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 531
Appendix 536
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2014 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2014 33
Number of Products under Development by Companies, H1 2014 35
Number of Products under Development by Companies, H1 2014 (Contd..1) 36
Number of Products under Development by Companies, H1 2014 (Contd..2) 37
Number of Products under Development by Companies, H1 2014 (Contd..3) 38
Number of Products under Development by Companies, H1 2014 (Contd..4) 39
Number of Products under Development by Companies, H1 2014 (Contd..5) 40
Number of Products under Development by Companies, H1 2014 (Contd..6) 41
Number of Products under Development by Companies, H1 2014 (Contd..7) 42
Number of Products under Development by Companies, H1 2014 (Contd..8) 43
Number of Products under Investigation by Universities/Institutes, H1 2014 45
Comparative Analysis by Late Stage Development, H1 2014 46
Comparative Analysis by Clinical Stage Development, H1 2014 47
Comparative Analysis by Early Stage Development, H1 2014 48
Comparative Analysis by Unknown Stage Development, H1 2014 49
Products under Development by Companies, H1 2014 50
Products under Development by Companies, H1 2014 (Contd..1) 51
Products under Development by Companies, H1 2014 (Contd..2) 52
Products under Development by Companies, H1 2014 (Contd..3) 53
Products under Development by Companies, H1 2014 (Contd..4) 54
Products under Development by Companies, H1 2014 (Contd..5) 55
Products under Development by Companies, H1 2014 (Contd..6) 56
Products under Development by Companies, H1 2014 (Contd..7) 57
Products under Development by Companies, H1 2014 (Contd..8) 58
Products under Development by Companies, H1 2014 (Contd..9) 59
Products under Development by Companies, H1 2014 (Contd..10) 60
Products under Development by Companies, H1 2014 (Contd..11) 61
Products under Development by Companies, H1 2014 (Contd..12) 62
Products under Investigation by Universities/Institutes, H1 2014 63
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2014 64
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 65
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 66
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Osiris Therapeutics, Inc., H1 2014 67
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca PLC, H1 2014 68
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline plc, H1 2014 69
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MedImmune, LLC, H1 2014 70
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 71
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H1 2014 72
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 73
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols, S.A., H1 2014 74
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H1 2014 75
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 76
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SkyePharma PLC, H1 2014 77
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2014 78
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2014 79
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H1 2014 80
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2014 81
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 82
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Laboratoires Pierre Fabre SA., H1 2014 83
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meda AB, H1 2014 84
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2014 85
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H1 2014 86
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ranbaxy Laboratories Limited, H1 2014 87
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 88
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H1 2014 89
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H1 2014 90
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alchemia Limited, H1 2014 91
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Almirall, S.A., H1 2014 92
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Lupin Limited, H1 2014 93
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Basilea Pharmaceutica AG, H1 2014 94
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medivir AB, H1 2014 95
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H1 2014 96
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Incorporated, H1 2014 97
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2014 98
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H1 2014 99
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dynavax Technologies Corporation, H1 2014 100
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioxyne Limited, H1 2014 101
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 102
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 103
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H1 2014 104
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H1 2014 105
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 106
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance, Inc., H1 2014 107
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synairgen plc, H1 2014 108
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2014 109
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orexo AB, H1 2014 110
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 111
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteo, Inc., H1 2014 112
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2014 113
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd., H1 2014 114
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alba Therapeutics Corporation, H1 2014 115
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2014 116
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 117
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2014 118
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2014 119
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H1 2014 120
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H1 2014 121
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H1 2014 122
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H1 2014 123
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MSM Protein Technologies, Inc., H1 2014 124
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AIM Therapeutics Inc., H1 2014 125
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hydra Biosciences, Inc., H1 2014 126
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theraclone Sciences, Inc., H1 2014 127
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H1 2014 128
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 129
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Noxxon Pharma AG, H1 2014 130
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TransTech Pharma, Inc., H1 2014 131
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Edmond Pharma Srl, H1 2014 132
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cempra, Inc., H1 2014 133
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 134
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 135
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SuppreMol GmbH, H1 2014 136
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H1 2014 137
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ikaria Inc., H1 2014 138
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., H1 2014 139
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asmacure Ltee, H1 2014 140
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Protagonist Therapeutics Inc., H1 2014 141
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MicroDose Therapeutx, Inc., H1 2014 142
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 143
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H1 2014 144
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 145
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H1 2014 146
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by N30 Pharmaceuticals, H1 2014 147
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H1 2014 148
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlycoMar Limited, H1 2014 149
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stempeutics Research Private Limited, H1 2014 150
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2014 151
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Clarassance, Inc., H1 2014 152
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 153
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014 154
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Selvita S.A, H1 2014 155
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals, Inc., H1 2014 156
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Corridor Pharmaceuticals Inc., H1 2014 157
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2014 158
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H1 2014 159
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rottapharm|Madaus, H1 2014 160
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 161
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by P2D Bioscience, H1 2014 162
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H1 2014 163
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 164
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Qu Biologics Inc., H1 2014 165
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 166
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 167
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H1 2014 168
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H1 2014 169
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 170
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Peptinnovate Limited, H1 2014 171
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by vida therapeutics inc., H1 2014 172
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 173
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ario Pharma Ltd, H1 2014 174
Assessment by Monotherapy Products, H1 2014 175
Assessment by Combination Products, H1 2014 176
Number of Products by Stage and Target, H1 2014 179
Number of Products by Stage and Mechanism of Action, H1 2014 186
Number of Products by Stage and Route of Administration, H1 2014 194
Number of Products by Stage and Molecule Type, H1 2014 197
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Recent Pipeline Updates, H1 2014 479
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2014 548
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2014 552
List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2014 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2014 33
Number of Products under Development by Companies, H1 2014 34
Number of Products under Investigation by Universities/Institutes, H1 2014 44
Comparative Analysis by Late Stage Development, H1 2014 46
Comparative Analysis by Clinical Stage Development, H1 2014 47
Comparative Analysis by Early Stage Products, H1 2014 48
Assessment by Monotherapy Products, H1 2014 175
Assessment by Combination Products, H1 2014 176
Number of Products by Top 10 Target, H1 2014 177
Number of Products by Stage and Top 10 Target, H1 2014 178
Number of Products by Top 10 Mechanism of Action, H1 2014 184
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 185
Number of Products by Top 10 Route of Administration, H1 2014 192
Number of Products by Stage and Top 10 Route of Administration, H1 2014 193
Number of Products by Top 10 Molecule Type, H1 2014 195
Number of Products by Stage and Top 10 Molecule Type, H1 2014 196
Table of Contents 2
Introduction 7
Chronic Obstructive Pulmonary Disease (COPD) Overview 8
Therapeutics Development 9
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies 11
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes 21
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance 23
Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies 27
Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes 40
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 41
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 152
Drug Profiles 175
Chronic Obstructive Pulmonary Disease (COPD) - Recent Pipeline Updates 456
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 525
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 529
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 531
Appendix 536
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2014 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2014 33
Number of Products under Development by Companies, H1 2014 35
Number of Products under Development by Companies, H1 2014 (Contd..1) 36
Number of Products under Development by Companies, H1 2014 (Contd..2) 37
Number of Products under Development by Companies, H1 2014 (Contd..3) 38
Number of Products under Development by Companies, H1 2014 (Contd..4) 39
Number of Products under Development by Companies, H1 2014 (Contd..5) 40
Number of Products under Development by Companies, H1 2014 (Contd..6) 41
Number of Products under Development by Companies, H1 2014 (Contd..7) 42
Number of Products under Development by Companies, H1 2014 (Contd..8) 43
Number of Products under Investigation by Universities/Institutes, H1 2014 45
Comparative Analysis by Late Stage Development, H1 2014 46
Comparative Analysis by Clinical Stage Development, H1 2014 47
Comparative Analysis by Early Stage Development, H1 2014 48
Comparative Analysis by Unknown Stage Development, H1 2014 49
Products under Development by Companies, H1 2014 50
Products under Development by Companies, H1 2014 (Contd..1) 51
Products under Development by Companies, H1 2014 (Contd..2) 52
Products under Development by Companies, H1 2014 (Contd..3) 53
Products under Development by Companies, H1 2014 (Contd..4) 54
Products under Development by Companies, H1 2014 (Contd..5) 55
Products under Development by Companies, H1 2014 (Contd..6) 56
Products under Development by Companies, H1 2014 (Contd..7) 57
Products under Development by Companies, H1 2014 (Contd..8) 58
Products under Development by Companies, H1 2014 (Contd..9) 59
Products under Development by Companies, H1 2014 (Contd..10) 60
Products under Development by Companies, H1 2014 (Contd..11) 61
Products under Development by Companies, H1 2014 (Contd..12) 62
Products under Investigation by Universities/Institutes, H1 2014 63
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2014 64
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2014 65
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 66
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Osiris Therapeutics, Inc., H1 2014 67
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca PLC, H1 2014 68
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline plc, H1 2014 69
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MedImmune, LLC, H1 2014 70
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 71
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H1 2014 72
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 73
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols, S.A., H1 2014 74
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H1 2014 75
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 76
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SkyePharma PLC, H1 2014 77
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2014 78
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ASKA Pharmaceutical Co., Ltd., H1 2014 79
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H1 2014 80
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2014 81
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 82
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Laboratoires Pierre Fabre SA., H1 2014 83
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meda AB, H1 2014 84
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2014 85
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H1 2014 86
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ranbaxy Laboratories Limited, H1 2014 87
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 88
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H1 2014 89
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H1 2014 90
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alchemia Limited, H1 2014 91
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Almirall, S.A., H1 2014 92
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Lupin Limited, H1 2014 93
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Basilea Pharmaceutica AG, H1 2014 94
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medivir AB, H1 2014 95
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H1 2014 96
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Incorporated, H1 2014 97
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2014 98
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H1 2014 99
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dynavax Technologies Corporation, H1 2014 100
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioxyne Limited, H1 2014 101
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H1 2014 102
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 103
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H1 2014 104
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H1 2014 105
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Neurim Pharmaceuticals Ltd, H1 2014 106
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance, Inc., H1 2014 107
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synairgen plc, H1 2014 108
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2014 109
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orexo AB, H1 2014 110
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 111
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteo, Inc., H1 2014 112
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2014 113
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd., H1 2014 114
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alba Therapeutics Corporation, H1 2014 115
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2014 116
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 117
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2014 118
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2014 119
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H1 2014 120
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H1 2014 121
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H1 2014 122
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H1 2014 123
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MSM Protein Technologies, Inc., H1 2014 124
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AIM Therapeutics Inc., H1 2014 125
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hydra Biosciences, Inc., H1 2014 126
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theraclone Sciences, Inc., H1 2014 127
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H1 2014 128
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Concert Pharmaceuticals, Inc., H1 2014 129
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Noxxon Pharma AG, H1 2014 130
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by TransTech Pharma, Inc., H1 2014 131
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Edmond Pharma Srl, H1 2014 132
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cempra, Inc., H1 2014 133
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2014 134
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 135
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SuppreMol GmbH, H1 2014 136
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H1 2014 137
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ikaria Inc., H1 2014 138
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., H1 2014 139
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asmacure Ltee, H1 2014 140
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Protagonist Therapeutics Inc., H1 2014 141
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MicroDose Therapeutx, Inc., H1 2014 142
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SelectX Pharmaceuticals, Inc., H1 2014 143
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H1 2014 144
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 145
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H1 2014 146
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by N30 Pharmaceuticals, H1 2014 147
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H1 2014 148
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlycoMar Limited, H1 2014 149
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stempeutics Research Private Limited, H1 2014 150
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2014 151
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Clarassance, Inc., H1 2014 152
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 153
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2014 154
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Selvita S.A, H1 2014 155
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals, Inc., H1 2014 156
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Corridor Pharmaceuticals Inc., H1 2014 157
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2014 158
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H1 2014 159
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rottapharm|Madaus, H1 2014 160
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 161
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by P2D Bioscience, H1 2014 162
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H1 2014 163
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Visionary Pharmaceuticals, Inc., H1 2014 164
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Qu Biologics Inc., H1 2014 165
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2014 166
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 167
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H1 2014 168
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H1 2014 169
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H1 2014 170
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Peptinnovate Limited, H1 2014 171
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by vida therapeutics inc., H1 2014 172
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 173
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ario Pharma Ltd, H1 2014 174
Assessment by Monotherapy Products, H1 2014 175
Assessment by Combination Products, H1 2014 176
Number of Products by Stage and Target, H1 2014 179
Number of Products by Stage and Mechanism of Action, H1 2014 186
Number of Products by Stage and Route of Administration, H1 2014 194
Number of Products by Stage and Molecule Type, H1 2014 197
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Recent Pipeline Updates, H1 2014 479
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2014 548
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2014 552
List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2014 32
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2014 33
Number of Products under Development by Companies, H1 2014 34
Number of Products under Investigation by Universities/Institutes, H1 2014 44
Comparative Analysis by Late Stage Development, H1 2014 46
Comparative Analysis by Clinical Stage Development, H1 2014 47
Comparative Analysis by Early Stage Products, H1 2014 48
Assessment by Monotherapy Products, H1 2014 175
Assessment by Combination Products, H1 2014 176
Number of Products by Top 10 Target, H1 2014 177
Number of Products by Stage and Top 10 Target, H1 2014 178
Number of Products by Top 10 Mechanism of Action, H1 2014 184
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 185
Number of Products by Top 10 Route of Administration, H1 2014 192
Number of Products by Stage and Top 10 Route of Administration, H1 2014 193
Number of Products by Top 10 Molecule Type, H1 2014 195
Number of Products by Stage and Top 10 Molecule Type, H1 2014 196
